Recent abolon transactions

Abolon advises on the sale of COAT-X, an innovator in high performance thin-film encapsulation technologies

Abolon has been the adviser to the shareholders of COAT-X, Switzerland, on its sale to the French surface functionalization and protection solutions provider Plasmalex group. The transaction has been closed on 25 April 2024. It was agreed not to disclose the purchase price. COAT-X is a leading solutions provider for high performance thin-film encapsulation technologies. The offering includes a broad range of parylene, ultra-tight multilayer and ALD barrier contract coating solutions and equipment to various industries ranging from medical technology over electronics to micromechanics.

Read more

Healthcare insights

How will new landmark legislation affect Germany’s private hospital groups

The new Hospital Structure Act could force small, low quality public sector hospitals to the wall. But it could also cap growth for big private operators. We examine likely scenarios.

Read more

Healthcare deal of the month

December 2015: Etac acquires Convaid

The Deal: In December 2015, Etac, a Sweden-based developer and manufacturer of mobility solutions and rehab products, acquired Convaid Products

Read more


Abolon is a strategy consulting and corporate finance company with an exclusive focus on the healthcare sector.

We pride ourselves on our specialist insights into the various segments of the healthcare markets in Europe and beyond.

Our global network in the healthcare sector provides us with unmatched dealflow of large and mid-sized healthcare opportunities.

Facts & figures

  • Healthcare forms an enormous ...
  • Stable healthcare sector attracts ...
  • The global pharmaceutical market ...
  • The healthcare sector offers ...
  • Abolon has advised on ...
  • Healthcare forms an enormous part of developed country's economy, contributing over 10 percent of gross domestic product (GDP).
  • Stable healthcare sector attracts record private equity investments.
  • The global pharmaceutical market is expected to grow from 995 $bn in 2011 to 1160 $bn in 2016
  • The healthcare sector offers numerous opportunities at low risk
  • Abolon has advised on 4 successful healthcare transactions in the last 18 months.